SIGY

US82674U2050

Market Closed - OTC Markets Other stock markets 12:27:32 2024-05-15 pm EDT			5-day change	1st Jan Change
5.25 ^USD	+5.00%		+5.00%	+10.99%

Feb. 20	Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer	CI

Reign Resources Corporation has Changed its Name to Sigyn Therapeutics, Inc

October 12, 2020 at 12:00 am EDT

On October 12, 2020, Reign Resources Corporation changed its name to Sigyn Therapeutics, Inc.

Latest news about SIGN THERPAR

Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer	Dec. 12	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Sigyn Therapeutics, Inc. Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep Trademark Application	23-05-17	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Sigyn Therapeutics, Inc. Announces Appointment of Annette Marleau as Chief Scientific Officer	23-04-11	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Sigyn Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Sigyn Therapeutics, Inc. Announces Cancer-Related Patent Submission	22-10-06	CI
Sigyn Therapeutics, Inc. Announces Board Changes, Effective October 10, 2022	22-10-04	CI
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients	22-09-14	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Sigyn Therapeutics, Inc. has filed an IPO in the amount of $9.2 million.	22-06-22	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board	22-04-26	CI
Sigyn Therapeutics, Inc. Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board	22-03-31	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Sigyn Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-03-20	CI
Sigyn Therapeutics, Inc. Appoints H. David Humes, MD to Its Scientific Advisory Board	22-03-15	CI
Sigyn Therapeutics, Inc. Appoints Alexander S. Yevzlin to its Scientific Advisory Board	22-03-09	CI
Sigyn Therapeutics, Inc. Appoints Jeremy Ferrell as Chief Financial Officer, Effective March 9, 2022	22-03-02	CI
Sigyn Therapeutics Announces Completion of Animal Studies	22-02-23	CI
Sigyn Therapeutics, Inc. Reports the Successful Completion of A Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis	21-12-01	CI

Sigyn Therapeutics, Inc. is a development-stage company. The Company is focused on creating therapeutic solutions that address unmet needs in global health. The Company's product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Its treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.

Sector

More about the company